OpenAI acquired Orchestra Bio, a drug development software startup, to bring AI-powered operations to life sciences R&D, the company announced.[1][2][3] Orchestra builds AI agents that help pharmaceutical teams monitor studies, track finances and resolve clinical trial scheduling issues, according to SiliconANGLE.[1] The startup’s staff and technology will join OpenAI’s Rosalind unit, which launched in April as a reasoning model for biology and drug discovery.[1] Terms were not disclosed, and OpenAI gave no timeline for when Orchestra’s agents will appear in its products.[1]